Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 1.53 g/t Au over 191.3m in infill drilling at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Vaxxinity Inc (EM) VAXX

Healthcare Biotechnology
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:VAXX)

Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

GlobeNewswire June 20, 2024

Vaxxinity Issues Shareholder Letter

GlobeNewswire April 19, 2024

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

GlobeNewswire April 19, 2024

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

GlobeNewswire March 28, 2024

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire March 27, 2024

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD(TM) 2024

GlobeNewswire March 7, 2024

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

GlobeNewswire February 15, 2024

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

GlobeNewswire February 13, 2024

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

GlobeNewswire January 30, 2024
View More News ››

Opinion & Analysis (EXPM:VAXX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:VAXX)

Vaxxinity, Inc. (NASDAQ:VAXX): A Promising Biotech Tackling

http://beyondspx.com/2024/08/02/vaxxinity-inc-nasdaqvaxx-a-promising-biotech-tackling-chronic-diseases-and-infectious-threats/
MikeTester - August 3, 2024
View more Bullboard ››

Lomiko Metals Inc.

Lomiko Metals Inc.

Lomiko Metals Inc. is a Canada-based company developing its flagship graphite property, La Loutre graphite in southern Quebec ...
View More »